Gossamer Bio Q1 2026 Earnings Call Insights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 33 minutes ago
0mins
Should l Buy GOSS?
Source: seekingalpha
- Clinical Data Interpretation: CEO Faheem Hasnain highlighted that PROSERA demonstrated a clinically meaningful improvement of 13.3 meters in 6-minute walk distance at week 24, with a p-value of 0.032, which, while statistically significant, did not meet the pre-specified 0.025 threshold, potentially impacting future regulatory approval.
- Cost Control Measures: The company implemented significant layoffs affecting approximately half of its workforce and sharply reduced operating expenses as PROSERA winds down, a strategy aimed at enhancing financial stability and optimizing resource allocation.
- Financial Status Update: As of March 31, 2026, Gossamer reported cash and cash equivalents and marketable securities totaling $99 million, with an expected cash runway extending into the first quarter of 2027, indicating a healthy short-term financial position.
- NDA Submission Plan: The company plans to submit its New Drug Application (NDA) in September 2026 and has scheduled a pre-NDA meeting with the FDA, with potential approval expected in the third quarter of 2027, laying the groundwork for future market launch.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GOSS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GOSS
Wall Street analysts forecast GOSS stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.340
Low
10.00
Averages
12.33
High
15.00
Current: 0.340
Low
10.00
Averages
12.33
High
15.00
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gossamer Bio Launches Exchange Offer for Convertible Notes
- Exchange Offer Initiated: Gossamer Bio has launched an exchange offer for its existing 5.00% Convertible Senior Notes, proposing to exchange them for up to $72 million in new 7.50% Convertible Senior Secured Notes, which is expected to improve the company's capital structure and reduce financial costs.
- High Support from Noteholders: Approximately 75.2% of existing noteholders have signed a transaction support agreement to back the exchange offer, reflecting market confidence in the company's restructuring plan and enhancing the liquidity of the bonds.
- Advantages of New Bond Terms: The new bonds will mature in 2030 with an interest rate of 7.50% and conversion rights, which are expected to attract more investors and enhance the company's financing capabilities and market competitiveness.
- Key Timeline: The exchange offer will expire on June 16, 2026, with an early tender deadline of June 1, 2026, ensuring timely participation will enable the company to successfully complete its debt restructuring and optimize its capital structure.
See More
Gossamer Bio Q1 2026 Earnings Call Insights
- Clinical Data Interpretation: CEO Faheem Hasnain highlighted that PROSERA demonstrated a clinically meaningful improvement of 13.3 meters in 6-minute walk distance at week 24, with a p-value of 0.032, which, while statistically significant, did not meet the pre-specified 0.025 threshold, potentially impacting future regulatory approval.
- Cost Control Measures: The company implemented significant layoffs affecting approximately half of its workforce and sharply reduced operating expenses as PROSERA winds down, a strategy aimed at enhancing financial stability and optimizing resource allocation.
- Financial Status Update: As of March 31, 2026, Gossamer reported cash and cash equivalents and marketable securities totaling $99 million, with an expected cash runway extending into the first quarter of 2027, indicating a healthy short-term financial position.
- NDA Submission Plan: The company plans to submit its New Drug Application (NDA) in September 2026 and has scheduled a pre-NDA meeting with the FDA, with potential approval expected in the third quarter of 2027, laying the groundwork for future market launch.
See More
Gossamer Bio Investors Class Action Reminder
- Lawsuit Deadline: Investors in Gossamer Bio must file a lead plaintiff motion by June 1, 2026, to participate in a class action lawsuit concerning securities purchased between June 16, 2025, and February 20, 2026, aimed at recovering losses from the stock price collapse.
- Stock Price Collapse: On February 23, 2026, Gossamer disclosed that its Phase 3 PROSERA study for pulmonary arterial hypertension failed to meet its primary endpoint, resulting in a stock price drop of $1.71, or 80.3%, closing at $0.42 per share, which severely impacted investors.
- False Statements Allegation: The class action lawsuit alleges that throughout the class period, the company made materially false and misleading statements and failed to disclose significant adverse facts about its business and operations, particularly regarding the treatment status of patients in Latin America.
- Legal Consultation Information: Investors seeking more information or wishing to participate in the lawsuit can contact Glancy Prongay Wolke & Rotter LLP, providing their contact details for further legal support and inquiries.
See More
Gossamer Bio Faces Class Action Lawsuit Over Trial Failures
- Lawsuit Background: Gossamer Bio, Inc. (NASDAQ:GOSS) is facing a class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, covering the period from June 16, 2025, to February 20, 2026, indicating significant investor dissatisfaction with the company's transparency.
- Stock Price Plunge: Following the trial results announcement, Gossamer's stock price plummeted by 80%, which not only undermined investor confidence but also prompted investigations by shareholder rights firms like Hagens Berman, potentially affecting the company's future financing capabilities.
- Trial Design Controversy: The lawsuit alleges that Gossamer had issues with trial design, particularly regarding patient recruitment and monitoring, as management previously claimed the drug could be a “first-in-class treatment for PAH,” yet failed to disclose potential flaws in the trial adequately.
- Listing Compliance Risks: On April 9, 2026, Gossamer revealed that it had not met the minimum share bid price ($1) required for continued listing on the Nasdaq Global Select Market since February 24, 2026, which could lead to delisting risks and further exacerbate investor concerns.
See More
Class Action Lawsuit Filed Against Gossamer Bio, Inc.
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Gossamer Bio, alleging violations of federal securities laws on behalf of all investors who purchased Gossamer securities between June 16, 2025, and February 20, 2026.
- False Statements Allegation: The complaint claims that Gossamer misled investors by touting positive results from its PROSERA study while concealing significant design flaws at Latin American testing sites, resulting in artificially inflated stock prices that harmed investors.
- Investor Action: Affected investors have until June 1, 2026, to request appointment as lead plaintiff in the case, allowing them to participate in any recovery without needing to serve as lead plaintiff.
- Law Firm's Expertise: Bronstein, Gewirtz & Grossman LLC specializes in securities fraud class actions and has recovered hundreds of millions for investors nationwide, highlighting its commitment to restoring investor capital and ensuring corporate accountability.
See More
Gossamer Bio Q1 Earnings Report Analysis
- Earnings Performance: Gossamer Bio reported a Q1 GAAP EPS of -$0.20, missing expectations by $0.06, indicating challenges in profitability that may affect investor confidence.
- Revenue Growth: The company achieved revenues of $16.96M, a 71.3% year-over-year increase, surpassing market expectations by $13.14M, suggesting a significant rise in product acceptance and demand that could lay the groundwork for future growth.
- Cash Reserves: As of March 31, Gossamer had $99 million in cash, cash equivalents, and marketable securities, providing ample liquidity to support ongoing R&D and market expansion, thereby enhancing financial stability.
- Regulatory Uncertainty: Cantor downgraded Gossamer Bio due to unclear regulatory pathways for seralutinib, which may raise investor concerns about the company's future direction and impact stock performance.
See More
Gossamer Bio Launches Exchange Offer for Convertible Notes
- Exchange Offer Initiated: Gossamer Bio has launched an exchange offer for its existing 5.00% Convertible Senior Notes, proposing to exchange them for up to $72 million in new 7.50% Convertible Senior Secured Notes, which is expected to improve the company's capital structure and reduce financial costs.
- High Support from Noteholders: Approximately 75.2% of existing noteholders have signed a transaction support agreement to back the exchange offer, reflecting market confidence in the company's restructuring plan and enhancing the liquidity of the bonds.
- Advantages of New Bond Terms: The new bonds will mature in 2030 with an interest rate of 7.50% and conversion rights, which are expected to attract more investors and enhance the company's financing capabilities and market competitiveness.
- Key Timeline: The exchange offer will expire on June 16, 2026, with an early tender deadline of June 1, 2026, ensuring timely participation will enable the company to successfully complete its debt restructuring and optimize its capital structure.
See More
Gossamer Bio Q1 2026 Earnings Call Insights
- Clinical Data Interpretation: CEO Faheem Hasnain highlighted that PROSERA demonstrated a clinically meaningful improvement of 13.3 meters in 6-minute walk distance at week 24, with a p-value of 0.032, which, while statistically significant, did not meet the pre-specified 0.025 threshold, potentially impacting future regulatory approval.
- Cost Control Measures: The company implemented significant layoffs affecting approximately half of its workforce and sharply reduced operating expenses as PROSERA winds down, a strategy aimed at enhancing financial stability and optimizing resource allocation.
- Financial Status Update: As of March 31, 2026, Gossamer reported cash and cash equivalents and marketable securities totaling $99 million, with an expected cash runway extending into the first quarter of 2027, indicating a healthy short-term financial position.
- NDA Submission Plan: The company plans to submit its New Drug Application (NDA) in September 2026 and has scheduled a pre-NDA meeting with the FDA, with potential approval expected in the third quarter of 2027, laying the groundwork for future market launch.
See More
Gossamer Bio Investors Class Action Reminder
- Lawsuit Deadline: Investors in Gossamer Bio must file a lead plaintiff motion by June 1, 2026, to participate in a class action lawsuit concerning securities purchased between June 16, 2025, and February 20, 2026, aimed at recovering losses from the stock price collapse.
- Stock Price Collapse: On February 23, 2026, Gossamer disclosed that its Phase 3 PROSERA study for pulmonary arterial hypertension failed to meet its primary endpoint, resulting in a stock price drop of $1.71, or 80.3%, closing at $0.42 per share, which severely impacted investors.
- False Statements Allegation: The class action lawsuit alleges that throughout the class period, the company made materially false and misleading statements and failed to disclose significant adverse facts about its business and operations, particularly regarding the treatment status of patients in Latin America.
- Legal Consultation Information: Investors seeking more information or wishing to participate in the lawsuit can contact Glancy Prongay Wolke & Rotter LLP, providing their contact details for further legal support and inquiries.
See More
Gossamer Bio Faces Class Action Lawsuit Over Trial Failures
- Lawsuit Background: Gossamer Bio, Inc. (NASDAQ:GOSS) is facing a class action lawsuit following its February 23, 2026 announcement that the PROSERA study failed to meet its primary endpoint, covering the period from June 16, 2025, to February 20, 2026, indicating significant investor dissatisfaction with the company's transparency.
- Stock Price Plunge: Following the trial results announcement, Gossamer's stock price plummeted by 80%, which not only undermined investor confidence but also prompted investigations by shareholder rights firms like Hagens Berman, potentially affecting the company's future financing capabilities.
- Trial Design Controversy: The lawsuit alleges that Gossamer had issues with trial design, particularly regarding patient recruitment and monitoring, as management previously claimed the drug could be a “first-in-class treatment for PAH,” yet failed to disclose potential flaws in the trial adequately.
- Listing Compliance Risks: On April 9, 2026, Gossamer revealed that it had not met the minimum share bid price ($1) required for continued listing on the Nasdaq Global Select Market since February 24, 2026, which could lead to delisting risks and further exacerbate investor concerns.
See More
Class Action Lawsuit Filed Against Gossamer Bio, Inc.
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Gossamer Bio, alleging violations of federal securities laws on behalf of all investors who purchased Gossamer securities between June 16, 2025, and February 20, 2026.
- False Statements Allegation: The complaint claims that Gossamer misled investors by touting positive results from its PROSERA study while concealing significant design flaws at Latin American testing sites, resulting in artificially inflated stock prices that harmed investors.
- Investor Action: Affected investors have until June 1, 2026, to request appointment as lead plaintiff in the case, allowing them to participate in any recovery without needing to serve as lead plaintiff.
- Law Firm's Expertise: Bronstein, Gewirtz & Grossman LLC specializes in securities fraud class actions and has recovered hundreds of millions for investors nationwide, highlighting its commitment to restoring investor capital and ensuring corporate accountability.
See More
Gossamer Bio Q1 Earnings Report Analysis
- Earnings Performance: Gossamer Bio reported a Q1 GAAP EPS of -$0.20, missing expectations by $0.06, indicating challenges in profitability that may affect investor confidence.
- Revenue Growth: The company achieved revenues of $16.96M, a 71.3% year-over-year increase, surpassing market expectations by $13.14M, suggesting a significant rise in product acceptance and demand that could lay the groundwork for future growth.
- Cash Reserves: As of March 31, Gossamer had $99 million in cash, cash equivalents, and marketable securities, providing ample liquidity to support ongoing R&D and market expansion, thereby enhancing financial stability.
- Regulatory Uncertainty: Cantor downgraded Gossamer Bio due to unclear regulatory pathways for seralutinib, which may raise investor concerns about the company's future direction and impact stock performance.
See More
